Articles tagged "Rejection"

2016 American Transplant Congress
Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients.
C.-D. Kim, J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim.
Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Background: Mycophenolic acid (MPA) is a widely used immunosuppressant to prevent acute rejection in kidney transplant recipients (KTRs). However, clinical significance of MPA therapeutic drug…
2016 American Transplant Congress
Impact of Early Acute Rejection (AR) on Pancreas Transplant (PT) Outcomes.
V. Kirchner, T. Dunn, A. Kukla, R. Kandaswamy, E. Finger.
University of Minnesota, Minneapolis.
Background: The role of early AR in long-term PT outcomes remains unclear. Despite reported high rate of AR (up to 40% in PTA), graft survival…
2016 American Transplant Congress
Mechanistic Insights into How Targeting of HDAC10 Promotes Foxp3+ Treg Cell Suppressive Activity, Gene Expression and Metabolism, and Enhances Allograft Survival.
S. Dahiya,¹ L. Wang,¹ U. Beier,^1,2 A. Angelin,¹ R. Han,¹ D. Wallace,^1,2 W. Hancock.^1,2
¹Children's Hospital of Philadelphia, Philadelphia; ²University of Pennsylvania, Philadelphia.
Foxp3+ T-regulatory (Treg) cells are key regulators of immune responses that can result in unwarranted inflammation and promote allograft rejection. From a theoretical perspective, targeting…
2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
X. Wen,¹ M. Casey,¹ A. Santos,¹ A. Hartzema,² K. Womer.¹
¹Department of Medicine, University of Florida, Gainesville, FL; ²Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…
2016 American Transplant Congress
Malignancies Contribute to Presensitization with Alloreactive T-Cells in Kidney Transplant Recipients.
T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany.
Alloreactive T-cells have been suggested to impact allograft outcome due to a higher incidence of acute rejection in the initial period after kidney transplantation. Knowledge…
2016 American Transplant Congress
Interaction Between Kidney Tissue Proteome and Humoral Immunity in Antibody Mediated Rejection.
A. Konvalinka,¹ A. Chruscinski,² S. Kim,¹ K. Tinckam,¹ I. Jurisica,³ R. John.⁴
¹Medicine/Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada; ²Medicine/Division of Cardiology, Toronto General Hospital, Toronto, ON, Canada; ³Medical Biophysics and Computational Science, University of Toronto, Toronto, ON, Canada; ⁴Pathology, Toronto General Hospital, Toronto, ON, Canada.
PURPOSE: Antibody-mediated rejection (AMR) is caused by antibodies against human leukocyte antigens (HLA) on graft endothelium, and non-HLA antibodies that target endothelial and epithelial proteins.…
2016 American Transplant Congress
Rapid Emergence of CD28^null Cells Following Ex Vivo Restimulation Is Associated with Belatacept Resistant Rejection.
M. Cortes, S. Laurie, B. Sayed, M. Ford.
Emory Transplant Center, Atlanta, GA.
Numerous studies have implicated donor-reactive memory T cells in mediating costimulation blockade resistant rejection (CoBRR) following treatment with belatacept. In humans, these memory T cells…
2016 American Transplant Congress
Plasma Endothelial Microvesicle Counts Indicate Allograft Rejection Following Kidney Transplantation.
D. Zecher,¹ A. Cumpelik,² B. Ruhland,¹ B. Banas,¹ H. Hopfer,³ M. Dickenmann,⁴ J. Schifferli.²
¹Nephrology, Regensburg University Hospital, Regensburg, Germany; ²Biomedicine, Basel University Hospital, Basel, Switzerland; ³Pathology, Basel University Hospital, Basel, Switzerland; ⁴Nephrology, Basel University Hospital, Basel, Switzerland.
Background: The release of surface-derived microvesicles (MV) is a common phenomenon of cellular activation and occurs specifically as a consequence of terminal complement complex assembly…
2016 American Transplant Congress
Quadruple Induction Regimen with Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Improves Graft Function without Increase in the Incidence of Microvascular Inflammation or De Novo Donor Specific Antibody Compared to the Standard Triple Regimen.
M. Miura, H. Higashiyama.
Department of Urology and Renal Transplantation Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan.
Objectives: Nephrotoxicity of calcineurin inhibitors (CNI) in kidney allografts has been a significant problem even with low exposure regimens. On the other hand, CNI-free regimen…
2016 American Transplant Congress
Postoperative Rebound of Anti-Blood Type Antibodies and Antibody-Mediated Rejection After ABO-Incompatible Living Related Kidney Transplantation – Is Prophylactic Treatment Necessary?
H. Ishida, T. Kondo, T. Shimizu, T. Nozaki, K. Tanabe.
Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
PURPOSE: The role of postoperative anti-ABO titers in acute rejection under our current immunosuppressive regimen remains unclear. Some institutions recommend postoperative therapeutic plasma exchange to…